Nakamura Tsutomu, Ota Masaho, Narumiya Kosuke, Sato Takuya, Shirai Yuji, Yamamoto Masakazu, Kuramochi Hidetoshi, Hayashi Kazuhiko
Dept. of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Japan.
Gan To Kagaku Ryoho. 2012 Feb;39(2):227-30.
Although chemotherapy consisting of cisplatin and 5-fluorouracil(CF)has been a standard regimen for esophageal cancer, it might be difficult to use continuously. This study evaluated the response and safety of docetaxel plus S-1 used as a second line therapy. We reviewed 21 patients(postoperatively, 11; after definitive chemoradiotherapy, 8; after chemotherapy, 2) who received chemotherapy between 2006 and 2010. Metastatic or recurrent disease was detected in the organs(n=8), lymph nodes(n=8), main tumors(n=3), mediastinum(n=1), and pleura(n=1). Docetaxel 30mg/m2 was infused every 2 weeks, and S-1 80mg/m2 was taken for 2 weeks, then with 2 weeks rest until progression. Almost all of the patients received docetaxel in the outpatient chemotherapy room. The median number of treatment cycles was 3, ranging from 1-12. Among the 14 patients with a therapeutic response, three(21%)achieved PR, 8 showed SD, and 3 had PD. Toxicity which included grade 3/4 was neutropenia in 6 patients, and anemia in one patient. After a follow-up of over one year, the median overall survival was 10 months, and the one-year survival rate was 38%. Docetaxel plus S-1 might be a feasible regimen as a second-line chemotherapy for metastasis or recurrence of esophageal cancer.
尽管顺铂和5-氟尿嘧啶组成的化疗方案（CF）一直是食管癌的标准治疗方案，但可能难以持续使用。本研究评估了多西他赛联合S-1作为二线治疗的疗效和安全性。我们回顾了2006年至2010年间接受化疗的21例患者（术后11例；根治性放化疗后8例；化疗后2例）。转移或复发疾病在器官（n = 8）、淋巴结（n = 8）、主要肿瘤（n = 3）、纵隔（n = 1）和胸膜（n = 1）中被检测到。多西他赛30mg/m²每2周静脉输注一次，S-1 80mg/m²服用2周，然后休息2周，直至疾病进展。几乎所有患者均在门诊化疗室接受多西他赛治疗。治疗周期的中位数为3个，范围为1 - 12个。在14例有治疗反应的患者中，3例（21%）达到PR，8例显示SD，3例为PD。包括3/4级的毒性反应为6例患者出现中性粒细胞减少，1例患者出现贫血。经过一年多的随访，中位总生存期为10个月，一年生存率为38%。多西他赛联合S-1可能是食管癌转移或复发二线化疗的可行方案。
